UltraBurst™
Introducing UltraBurst, a novel, innovative excipient platform for ODTs. Delivering the fastest disintegration time (<10seconds DT) of any preformulated products on the market while maintaining best in class hardness, friability, and API loading.
UltraBurst™ eBook
Our new UltraBurst™ eBook has an abundance of information that helps formulators make informed decisions and overcome obstacles in their development process, ultimately leading to the creation of safe, effective, and patient-friendly dosage forms.
As the founder of the first co‑processed ODT excipient platform—Pharmaburst™, incorporated into more than 60 FDA‑approved drug products worldwide—SPI Pharma continues to advance patient‑centric ODT innovation. UltraBurst™ builds on that heritage with enhanced performance, improved manufacturability, and a platform approach that supports both branded and generic development.
UltraBurst™ enables:
- Rapid‑onset (<10seconds DT) positioning across CNS, pain, pediatric, geriatric, and acute‑care segments
- Suspension → mini‑tablet conversion to reduce contamination/stability issues and improve dose accuracy
- Can be used sublingually to allow rapid absorption through the oral tissues
- Generic Rx line extensions and off‑patent product differentiation without API or indication changes
- 505(b)(2) lifecycle strategies that extend product value through reformulation
- Improved patient compliance with convenient, easy‑to‑administer ODT formats
Related Technologies
